Publication date: Jul 23, 2019
This post was originally published on this site EIP Pharma is launching a proof-of-concept Phase 2 clinical trial to assess the ability of therapeutic candidate neflamapimod to treat cognitive dysfunction in patients with early-stage Huntington’s disease. -We believe that neflamapimod has the potential to treat cognitive impairments associated with Huntington’s disease and can therefore benefit patients early in the course of their disease,” John Alam, MD, founder and CEO of EIP Pharma, said in a press release. Neflamapimod is also being tested in a Phase 2 trial (NCT02423122) in Alzheimer’s disease and has led to significant improvements in episodic memory function in patients with early disease. The post Phase 2 Trial Recruiting Early-stage Huntington’s Patients to Test Neflamapimod for Improving Cognition appeared first on Huntington’s Disease News. The post Phase 2 Trial Recruiting Early-stage Huntington’s Patients to Test Neflamapimod for Improving Cognition appeared first on BioNewsFeeds.
- EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in Patients with Huntington’s Disease
- EIP Pharma Announces Presentation of Preclinical Data Demonstrating Effects of p38α Kinase Inhibitor Neflamapimod on the Neurodegenerative Process